Table 1 Studies reporting prevalence and associations of anemia or iron deficiency amongst individuals with AF
From: Anemia and iron deficiency in patients with atrial fibrillation
Study | Study type | Study size | Population type | Anemia, n (%) | Iron deficiency, n (%) | Outcomes studied |
|---|---|---|---|---|---|---|
Shireman, 2006 [77] | Cohort study | 26,345 | Inpatient | 2107 (8) | – | Bleeding |
Sharma, 2009 [78] | Cohort study | 13,067 | Inpatient | 7056 (54) | – | All-cause mortality |
Park, 2011 [79] | Cohort study | 488 | Outpatient | – | – | All-cause mortality |
Suzuki, 2012 [80] | Cohort study | 1942 | Inpatient | 94 (5) | – | Mortality and hospitalization |
Lip, 2012 [81] | Cohort study | 7156 | Inpatient | 71 (1) | – | Bleeding |
Friberg, 2012 [82] | Cohort study | 90,490 | Inpatients and outpatients | – | – | Bleeding |
Manzano-Fernandez, 2012 [83] | Cohort study | 285 | Inpatient | 105 (37) | – | Bleeding |
Takabayashi, 2014 [84] | Cohort study | 2774 | Outpatient | 471 (17) | – | Hospitalization and major bleeding |
Puurunen, 2014 [65] | Cohort study | 861 | Inpatient | 258 (30) | – | Bleeding and composite all-cause mortality, non-fatal MI, TIA, stroke, bleeding |
Goodman, 2014 [85] | Secondary analysis of RCT | 14,236 | Anticoagulant trial | 1976 (14) | – | Bleeding |
Westenbrink, 2015 [10] | Secondary analysis of RCT | 17,796 | Anticoagulant trial | 2223 (13) | – | Thromboembolism, all-cause mortality, MI, bleeding, stroke |
Sherwood, 2015 [86] | Secondary analysis of RCT | 14,236 | Anticoagulant trial | 1993 (14) | – | Bleeding |
Lee, 2015 [87] | Cohort study | 166 | Outpatient | 54 (33) | – | Mortality and hospitalization for heart failure |
O’Brien, 2015 [88] | Cohort study | 7411 | Outpatient | 2742 (37) | – | Bleeding |
Dodson, 2016 [89] | Cross sectional study | 31,951 | Inpatients and outpatients | 6514 (20) | – | Bleeding |
Hori, 2016 [90] | Secondary analysis of RCT | 1278 | Anticoagulant trial | – | – | Bleeding |
Kobayashi, 2016 [91] | Cohort | 227 | Inpatient | 104 (46) | – | Bleeding |
Li, 2016 [92] | Cohort | 4632 | Inpatients and outpatients | 324 (7) | – | All-cause mortality |
Westenbrink, 2017 [11] | Secondary analysis of RCT | 18,103 | Anticoagulant trial | 2288 (12.5) | – | All-cause mortality, major bleeding, stroke, systemic embolism |
Aisenberg, 2018 [93] | Secondary analysis of RCT | 21,026 | Anticoagulant trial | 9885 (47) | – | Bleeding |
Perera, 2018 [94] | Secondary analysis of RCT | 7554 | Anticoagulant trial | 1888 (25) | – | All-cause mortality |
Keskin, 2018 [73] | Cohort study | 101 | Outpatient | 31 (30.7) | 48 (47.5) | ID/Haematinic deficiencies compared to control group |
Bonde, 2019 [9] | Cohort study | 18,734 | Inpatient | 6358 (34) | – | Stroke, thromboembolism, major bleeding |
An, 2019 [95] | Cohort study | 4169 | Outpatient | 1547 (37) | – | Stroke, systemic embolism, bleeding, and mortality |
Tiili, 2019 [96] | Cohort study | 53,953 | Outpatient | 1619 (3) | – | Bleeding |
Kuronuma, 2019 [97] | Cohort study | 3237 | Outpatient | – | – | All cause, cardiovascular and non-cardiovascular mortality |
Fu, 2019 [98] | Cohort study | 219 | Inpatient | – | – |  |
Kodani, 2020 [99] | Cohort study | 6536 | Outpatient | 1015 (16) | – | Thromboembolism, all-cause mortality |
An, 2020 [69] | Cohort study | 4169 | Outpatient | 1547 (37) | – | Thromboembolism, bleeding, heart failure |
Krittayaphong, 2021 [67] | Cohort study | 1562 | Outpatient | 518 (33) | – | Thromboembolism, bleeding, heart failure, mortality |
Cross-sectional | 5,975,241 | Inpatient | – | 152,059 (3) | Length of stay, hospitalization costs, myocardial infarction, vasopressor use, mechanical ventilation, kidney injury, mortality | |
Al-Hussainy, 2021 [101] | Cohort study | 41,321 | Outpatient | 11,812 (29) | – | Stroke, bleeding |
Hashimoto, 2021 [68] | Cohort study | 1677 | Outpatient | 378 (23) | – | Heart failure, bleeding, quality of life |
Zhang, 2022 [100] | Cohort study | 18,106 | Outpatient | 2500 (14) | – | Bleeding, cardiovascular and all-cause mortality |